Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases

Eitemau Tebyg

• Receptor activator of NF-κB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment
  gan: Huang, L, et al.
  Cyhoeddwyd: (2003)
• Receptor Activator of NF-κB Ligand (RANKL) Protects Against Hepatic Ischemia/Reperfusion Injury in Mice
  gan: Sakai, Nozomu, et al.
  Cyhoeddwyd: (2012)
• RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice
  gan: Fujiwara, Yuko, et al.
  Cyhoeddwyd: (2016)
• NF-κB signaling participates in both Receptor Activator of NF-κB Ligand- (RANKL) and interleukin-4- (IL-4) induced macrophage fusion: Receptor cross-talk leads to alterations in NF-κB pathways
  gan: Yu, Minjun, et al.
  Cyhoeddwyd: (2011)
• Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
  gan: Martin Widschwendter, et al.
  Cyhoeddwyd: (2015-10-01)